Shuttle Pharmaceuticals ...

NASDAQ: SHPH · Real-Time Price · USD
3.62
0.08 (2.26%)
At close: Aug 14, 2025, 3:59 PM
3.44
-4.97%
Pre-market: Aug 15, 2025, 07:10 AM EDT

Company Description

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.

Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers.

The company was founded in 2012 and is based in Rockville, Maryland.

Shuttle Pharmaceuticals Inc.
Shuttle Pharmaceuticals  Inc. logo
Country United States
IPO Date Aug 31, 2022
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 9
CEO Anatoly Dritschilo

Contact Details

Address:
One Research Court
Gaithersburg, Maryland
United States
Website https://www.shuttlepharma.com

Stock Details

Ticker Symbol SHPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001757499
CUSIP Number 825693401
ISIN Number US8256934014
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Christopher Robert Cooper BBA, M.B.A., MBA Interim Co-Chief Executive Officer
Dr. Anatoly Dritschilo M.D. Co-Founder, Co-Chief Executive Officer, Chief Scientific Officer & Chairman of the Board
Peter Dale Dritschilo M.B.A., M.D. President & Chief Operating Officer
Timothy J. Lorber CPA Chief Financial Officer
Dr. Milton Brown CSC, M.D., Ph.D. Co-Founder
Dr. Mira Jung Ph.D. Co-Founder & Chief Scientific Officer for Biology
Dr. Tyvin A. Rich M.D. Chief Clinical Officer & Chief Medical Officer
Michael P. Vander Hoek Vice President for Operations and Regulatory

Latest SEC Filings

Date Type Title
Aug 14, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 13, 2025 4 Filing
Aug 12, 2025 4 Filing
Aug 12, 2025 4 Filing
Aug 12, 2025 4 Filing
Aug 12, 2025 4 Filing
Aug 13, 2025 10-Q Quarterly Report
Aug 11, 2025 424B3 Filing
Aug 05, 2025 S-1 Filing
Jul 30, 2025 8-K Current Report